LevitasBio’s Post

Vivani announced today that our first-in-human study, LIBERATE-1™, has initiated screening and enrollment at two centers in Australia to investigate the safety, tolerability and full pharmacokinetic profile of our GLP-1 (exenatide) implant. “Transitioning to a clinical stage biopharmaceutical company is a major milestone for our company and allows us to determine if the very encouraging results from our animal studies will translate to overweight or obese study subjects,” said Adam Mendelsohn, Ph.D., Vivani President and Chief Executive Officer. Read more on this announcement: https://lnkd.in/dzvem33B. #GLP1 #WeightLossDrugs

Optimisation of workflows is what we do at Genovis - this is yet another example - now with a RNAase inhibitor in collaboration with SEQURNA AB #genovis #RNAaseinhibitor

Thoughts on this? >> TCGX and JPM help Pathalys raise $105M to go up against Amgen in subset of kidney disease >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharma #pharmaceutical #biotech

Ligand’s Captisol technology platform has helped optimize the solubility and stability of drugs for some of the world’s leading biopharmaceutical companies including Merck Pfizer Amgen and Gilead Sciences. Today there are more than 15 Captisol-enabled™ products approved worldwide. The leaders of our Captisol team, Drs. Vince Antle and James Pipkin, recently sat down with Lawrence Business Magazine to discuss how this unique technology has changed how drugs are developed and formulated. Read the article here: https://bit.ly/4bRjJtv

Read our case study, Leading Bio-Pharma Company Adopts Pristima for End-to-End Preclinical Research, to discover how one of the world's foremost biopharmaceutical giants overhauled its preclinical research dynamics with a powerful all-in-one preclinical solution. Learn how a unified preclinical LIMS solution can transform the way you manage preclinical data, leading to significant time savings, increased efficiency, and ultimately, a higher return on your investment. Access case study. https://hubs.la/Q02Z34yB0

Zencore Biologics, a portfolio company of Qiming Venture Partners, has entered into a strategic commercialization production agreement with DualityBio, marking a significant milestone in their collaboration. This agreement strengthens their long-term partnership in large-scale production and supply, while also paving the way for future innovations and global market expansion. Jianxin Chen, Chairman and CEO of Zencore Biologics, said, "Zencore Biologics is committed to advancing the scaling and internationalization of biopharmaceutical production. DualityBio, a leader in ADC innovation, will continue to develop next-generation ADCs, including bispecific ADCs, novel payload mechanism ADCs, and auto-immune ADCs, on its path to becoming a global leader in ADC biopharmaceuticals. We are honored to collaborate with DualityBio and support them in delivering high-quality, cost-effective commercial production." #Biotechnology #ADCInnovation #Commercialization #GlobalExpansion #Biopharmaceuticals #StrategicPartnership #QimingPortfolio #QimingHealthcare

Which topics are trending in the biopharmaceutical industry? For a decade, BEBPA (Biopharmaceutical Emerging Best Practices Association) has hosted an annual Host Cell Protein (HCP) Conference, bringing together industry experts and regulatory representation to discuss the latest advancements and best practices in impurity analysis. BEBPA is an independent, nonprofit organization founded to foster collaboration and raise biopharmaceutical development and manufacturing standards. Through its conferences and workshops, BEBPA has become a cornerstone of knowledge-sharing in our industry, providing a platform to address some of the most complex and emerging challenges. From Alphalyse, Thomas Kofoed, Ejvind Mørtz, and Rikke Raaen Lund have taken turns attending the BEBPA HCP Conference every year since 2014. Curious to know what they all learned at this year’s conference? Find their summaries of the - highly relevant - presentations they attended here: alphalyse.com/bebpa-2024

Curious if your Phase 1 trial would benefit from having a DMC, and how the DMC process would be different from later phase trials? See what Kent, Bill and I have to say about that.